GRI Bio reports positive Phase 2a gene expression data for GRI-0621 in IPF

GRI Bio, Inc.

Phase 2a gene expression data shows significant improvements in lung injury, fibroblast activation, and fibrosis-resolution genes vs placebo.
Data support basement membrane repair and AT2-to-AT1 epithelial cell transition, suggesting lung regeneration.
GRI-0621 met primary safety endpoint and multiple secondary endpoints; exploratory FVC improved vs standard of care.
CEO states data exceed expectations, reinforcing potential as a disease-modifying therapy for IPF.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.